This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Affymax And Takeda Announce OMONTYS® Data Presentations At The American Society Of Nephrology Kidney Week 2012

Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA), today announced that multiple abstracts on OMONTYS ® (peginesatide) Injection have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2012 taking place October 30 – November 4, 2012 in San Diego, Calif.

ASN will feature eight OMONTYS presentations (one oral session; seven poster sessions), six of which include data from the Phase 3 clinical program. Three other posters accepted for presentation highlight findings from observational studies on anemia management. Details of the presentations at ASN Kidney Week 2012 follow:

Thursday, November 1, 2012

  • Intravenous (IV) Iron Use in U.S. Hemodialysis Patients Receiving Peginesatide for Anemia Due to Chronic Kidney Disease (Provenzano, et al.)Oral Program # TH-OR097: 4:30 p.m.-6:30p.m.
  • Candidate Action Mechanisms of Peginesatide-Induced Erythropoiesis (Verma, et al.)Poster Board # TH-PO180: 10 a.m.-12 p.m.
  • Efficacy of Peginesatide Versus Epoetin by Baseline Characteristics in Hemodialysis Patients with Anemia Due to Chronic Kidney Disease (CKD) (Levin, et al.)Poster Board # TH-PO823: 10 a.m. -12 p.m.

Friday, November 2, 2012:

  • Initial Dose Stability After Conversion to Peginesatide in Hemodialysis Patients (Schiller, et al.)Poster Board # FR-PO261: 10 a.m.-12 p.m.
  • Peginesatide Immunogenicity in Clinical Studies of Chronic Kidney Disease Patients (Schatz, et al.)Poster Board # FR-PO262: 10 a.m.-12 p.m.
  • Hemoglobin Control and Dose Alterations with Peginesatide Versus Epoetin for Hemodialysis Patients (Spinowitz, et al.)Poster Board # FR-PO260: 10 a.m.-12 p.m.
  • Pharmacokinetics: Pharmacodynamics of Peginesatide in Patients with Chronic Kidney Disease on Dialysis (Czerniak, et al.)Poster Board # FR-PO837: 10 a.m.-12 p.m.
  • Missed Dialysis Sessions Result in Increased Erythropoiesis-Stimulating Agent Use (Bonds, et al.)Poster Board # FR-PO236: 10 a.m.-12 p.m.
  • Persistent Increases in ESA Utilization Following Hospitalization of End-Stage Renal Disease Patients (Bonds, et al.)Poster Board # FR-PO237: 10 a.m.-12 p.m.

Saturday, November 3, 2012:

  • Relationship Between Baseline Inflammatory Status and Cardiovascular Events in Hemodialysis Patients on Peginesatide or Epoetin (Locatelli, et al.)Poster Board # SA-PO629: 10 a.m.-12 p.m.
  • Impact of Frequent Hemoglobin Measurement and Erythropoiesis-Stimulating Agent Dose Titration on Hemoglobin Stability in Dialysis (Szczech, et al.)Poster Board # SA-PO643: 10 a.m.-12 p.m.

*Note: All times are listed in Pacific Time

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,200.42 -88.21 -0.48%
S&P 500 2,108.25 -9.14 -0.43%
NASDAQ 4,978.6030 -29.4930 -0.59%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs